Clinton Yam, MD, MS

Peer-Reviewed Articles

1. Stowers CE, Wu C, Lorenzo G, Hormuth DA 2nd, Yam C, Ma J, Rauch GM, Yankeelov TE. Characterizing Tumor Cell Movement in Partial Differential Equation Models of Triple-Negative Breast Cancer Receiving Neoadjuvant Therapy. Ann Biomed Eng, 2026. e-Pub 2026. PMID: 42678654.
2. Yan, Y, Lin, Y, Kumar, T, Bai, S, Thennavan, A, Li, J, Sei, E, Tran, TM, Hu, M, Rao, M, Tang, C, He, S, Casasent, A, Ravenberg, EE, Rauch, GM, Clayborn, A, Tripathy, D, Thompson, A, Lim, B, Huo, L, Moulder, S, Yam, C, Navin, N. Ecotypes of triple-negative breast cancer in response to chemotherapy. Nature 654(8120):1088-1097, 2026. e-Pub 2026. PMID: 42129561.
3. Singareeka Raghavendra, A, Tarasov, A, Mouabbi, JA, Evdokimova, A, Smirnov, V, Rumyantsev, K, Barcenas, CH, Layman, RM, Savin, E, Lim, B, Pohlmann, PR, Damodaran, S, Hensley, M, Makani, N, Ogloblina, A, Fowler, N, Giordano, SH, Bagaev, A, Yam, C, Tripathy, D. Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC). Journal of Clinical Oncology 44:e13080-e13080, 2026. e-Pub 2026.
4. Lee, KL, Yam, C, Zhao, L, Bassett Jr, R, Song, X, Thompson, A, White, JB, Layman, RM, Huo, L, Gutierrez, AM, Valero, V, Ueno, NT, Litton, J, Zhang, J, Ravenberg, EE, Korkut, A, Adrada, BE, Candelaria, RP, Rauch, GM, Tripathy, D, Shaitelman, SF, Arun, BK. Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial. Breast Cancer Research and Treatment 217(2), 2026. e-Pub 2026. PMID: 42223695.
5. Huo, X, Moseley, T, Adrada, BE, Yam, C, Huo, L, Guirguis, MS, Patel, MM, Leung, J, Whitman, GJ, Candelaria, RP, Lane, DL, Yang, WT, Sun, J, Litton, J, Valero, V, Arun, BK, Hwang, K, Wei, P, Ma, J, Rauch, GM. DCE-MRI for assessment of pathologic complete response after completion of neoadjuvant therapy in triple-negative breast cancer patients. Journal of Clinical Oncology 44:611, 2026. e-Pub 2026.
6. Seth S, Yam C, Huo L, Lim B, Rinkenbaugh AL, White JB, Ravenberg EE, Song X, Litton JK, Tripathy D, Valero V, Damodaran S, Arun B, Ueno NT, Lucci A, Thompson AM, Mittendorf EA, Rauch GM, Adrada B, Candelaria RP, Ding Q, Powell RT, Abuhadra NK, Zhang J, Futreal A, Draetta GF, Piwnica-Worms H, Symmans WF, Chang JT, Moulder SL. The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer. Breast Cancer Res 28(1), 2026. e-Pub 2026. PMID: 42093035.
7. Akkoc Mustafayev, FN, Fountzilas, E, Munsell, M, Layman, RM, Yam, C, Gutierrez, AM, Albarracin, C, Ahmed, Z, Schlacher, K, Tainer, J, Arun, BK. Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors. Cancers 18(8), 2026. e-Pub 2026. PMID: 42073582.
8. Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Banuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med 394(4):354-366, 2026. e-Pub 2026. PMID: 41564397.
9. Christenson, C, Wu, C, Hormuth, DA, Ma, J, Yam, C, Rauch, GM, Yankeelov, TE. Personalizing neoadjuvant chemotherapy regimens for triple-negative breast cancer using a biology-based digital twin. npj Systems Biology and Applications 11(1), 2025. e-Pub 2025. PMID: 40410237.
10. Guirguis, MS, Adrada, BE, Yam, C, Tripathy, D, Candelaria, RP, Yang, W, Patel, MM, Moseley, T, Perez, F, Whitman, GJ, Leung, J, Le-Petross, H, Lane, DL, Huo, L, Litton, J, Valero, V, Hunt, KK, Arun, BK, Mohamed, R, Sun, J, Korkut, A, Xu, Z, Pashapoor, S, White, JB, Son, JB, Thompson, A, Wei, P, Ma, J, Moulder, S, Rauch, GM. Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025. PMID: 41266347.
11. Stowers CE, Wu C, Yam C, Ma J, Rauch GM, Yankeelov TE. Predicting the response of triple negative breast cancer to neoadjuvant systemic therapy via biology-based modeling and habitat analysis. Sci Rep 15(1):42111, 2025. e-Pub 2025. PMID: 41298623.
12. Guirguis MS, Adrada BE, Yam C, Tripathy D, Candelaria R, Yang W, Patel M, Moseley T, Perez F, Whitman GJ, Leung JWT, Le-Petross H, Lane DL, Huo L, Litton JK, Valero V, Hunt KK, Arun B, Mohamed R, Sun J, Korkut A, Xu Z, Pashapoor S, White J, Son JB, Thompson A, Wei P, Ma J, Moulder S, Rauch GM. Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer. NPJ Breast Cancer 11(1):129, 2025. e-Pub 2025. PMID: 41266347.
13. Adrada BE, Guirguis MS, Huo L, Yam C, Tripathy D, Candelaria R, Yang W, Patel M, Moseley T, Whitman GJ, Leung JWT, Le-Petross H, Lane DL, Abuhadra N, Litton J, Valero V, Hunt KK, Arun B, Mohamed R, Sun J, Korkut A, Pashapoor S, White J, Thompson A, Wei P, Ma J, Moulder S, Rauch GM. Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. JCO Precis Oncol 9:e2500410, 2025. e-Pub 2025. PMID: 41411609.
14. Rinkenbaugh AL, Qi Y, Cai S, Shao J, Hancock F, Jeter-Jones SL, Zhang X, Powell E, Huo L, Lau R, Fu C, Gould R, den Hollander P, Ravenberg EE, White JB, Rauch GM, Arun B, Yam C, Thompson AM, Echeverria GV, Moulder SL, Symmans WF, Chang JT, Piwnica-Worms H. An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naive and Longitudinal Samples During Neoadjuvant Chemotherapy. Cancer Res 85(21):4062-4080, 2025. e-Pub 2025. PMID: 40801311.
15. Nanda, R, Yam, C, Spring, L, Bhave, M, Ntalla, I, Valdez, T, Stwalley, B, Liang, C, Wu, WH, Sjekloca, N, Sadetsky, N, Lai, C, Kalinsky, K. Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40479864.
16. Wu C, Lima EABF, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital twins to improve treatment response of breast cancer by optimizing neoadjuvant chemotherapy regimens. NPJ Digit Med 8(1):195, 2025. e-Pub 2025. PMID: 40195521.
17. Xu Z, Zhou Z, Son JB, Feng H, Adrada BE, Moseley TW, Candelaria RP, Guirguis MS, Patel MM, Whitman GJ, Leung JWT, Le-Petross HTC, Mohamed RM, Panthi B, Lane DL, Chen H, Wei P, Tripathy D, Litton JK, Valero V, Huo L, Hunt KK, Korkut A, Thompson A, Yang W, Yam C, Rauch GM, Ma J. Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. Cancers (Basel) 17(6), 2025. e-Pub 2025. PMID: 40149299.
18. Reddy, TP, Puri, A, Guzman-Rojas, L, Thomas, C, Qian, W, Zhou, J, Zhao, H, Mahboubi, B, Oo, A, Cho, YJ, Kim, B, Thaiparambil, J, Rosato, RR, Martinez, KO, Chervo, MF, Ayerbe, C, Giese, N, Wink, D, Lockett, S, Wong, ST, Chang, J, Krishnamurthy, S, Yam, C, Moulder, S, Piwnica-Worms, H, Meric-Bernstam, F, Chang, J. NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39737957.
19. Wang, X, Zhao, L, Song, X, Wu, X, Krishnamurthy, S, Semba, T, Shao, SH, Knafl, M, Coffer, LW, Alexander, A, Vines, A, Bopparaju, S, Woodward, W, Chu, RA, Zhang, J, Yam, C, Loo, LW, Nasrazadani, A, Huong, LP, Woodman, SE, Futreal, A, Zhang, S, Zhang, Q, Xu, M, Wistuba, II, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Song, P, Shaw, KR, Prabhakaran, S, Marques-Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Lu, W, Little, L, Lang, W, Kinyua, W, Khanduri, I, Jiang, M, Jacob, J, Jackson, S, Gite, S, Garcia-Prieto, C, Arrechedera, C, Tripathy, D. Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39558017.
20. Rinkenbaugh AL, Qi Y, Cai S, Shao J, Hancock F, Jeter-Jones S, Zhang X, Powell E, Huo L, Lau R, Fu C, Gould R, den Hollander P, Ravenberg EE, White JB, Rauch GM, Arun B, Yam C, Thompson AM, Echeverria GV, Moulder SL, Symmans WF, Chang JT, Piwnica-Worms H. An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naive and longitudinal samples throughout neoadjuvant chemotherapy. bioRxiv, 2024. e-Pub 2024. PMID: 39651299.
21. Stowers CE, Wu C, Xu Z, Kumar S, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiol Artif Intell 7(1):e240124, 2024. e-Pub 2024. PMID: 39503605.
22. Kalinsky K, Spring L, Yam C, Bhave MA, Ntalla I, Lai C, Sjekloca N, Stwalley B, Stokes M, Taylor A, Nanda R. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Research and Treatment 208(1):203-214, 2024. e-Pub 2024. PMID: 38904892.
23. Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
24. Chen JH, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, Kuerer HM, Meas S, Sarli VN, Korkut A, White JB, Rauch GM, Tripathy D, Arun BK, Barcenas CH, Yam C, Sethi H, Rodriguez AA, Liu MC, Moulder SL, Lucci A. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer 24(1):1016, 2024. e-Pub 2024. PMID: 39148033.
25. Mohamed RM, Panthi B, Adrada BE, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed B, Scoggins ME, Son JB, Thompson A, Tripathy D, Valero V, Wei P, White J, Whitman GJ, Xu Z, Yang W, Yam C, Ma J, Rauch GM. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep 14(1):16073, 2024. e-Pub 2024. PMID: 38992094.
26. Lim, B, Seth, S, Yam, C, Huo, L, Fujii, T, Lee, J, Bassett Jr, R, Nasser, S, Ravenberg, L, White, JB, Clayborn, A, Guerra, G, Litton, J, Damodaran, S, Layman, RM, Valero, V, Tripathy, D, Lewis, MT, Dobrolecki, LE, Lei, JT, Candelaria, RP, Arun, BK, Rauch, GM, Zhao, L, Zhang, J, Ding, Q, Symmans, WF, Chang, J, Thompson, A, Moulder, S, Ueno, NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38838676.
27. Iwase, T, Cohen, E, Gao, H, Alexander, A, Kai, M, Chiv, VY, Wang, X, Krishnamurthy, S, Liu, D, Shen, Y, Kida, K, Reuben, A, Layman, RM, Ramirez, DL, Tripathy, D, Moulder, S, Yam, C, Valero, V, Lim, B, Reuben, JM, Ueno, NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clinical Cancer Research 30(11):2424-2432, 2024. e-Pub 2024. PMID: 38629963.
28. Basho, RK, Zhao, L, White, JB, Huo, L, Bassett Jr, R, Mittendorf, EA, Thompson, A, Litton, J, Ueno, NT, Arun, BK, Lim, B, Valero, V, Tripathy, D, Zhang, J, Adrada, BE, Santiago, L, Ravenberg, EE, Seth, S, Yam, C, Moulder, S, Damodaran, S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38484209.
29. Woodfin, AA, Yam, C, Teshome, M, Kuerer, HM, Hunt, KK, Meric-Bernstam, F, Schaverien, MV, Barcenas, CH, Sun, SX. Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Annals of surgical oncology 31(2):974-980, 2024. e-Pub 2024. PMID: 37973647.
30. Wang, J, Peng, Y, Sun, H, Aung, PP, Resetkova, E, Yam, C, Sahin, AA, Huo, L, Ding, Q. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Archives of Pathology and Laboratory Medicine 148(2):200-205, 2024. e-Pub 2024. PMID: 37074839.
31. Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging 60(4):1367-1376, 2024. e-Pub 2024. PMID: 38294179.
32. Garber, HR, Basu, S, Jindal, S, He, Z, Chu, K, Singareeka Raghavendra, A, Yam, C, Santiago, L, Adrada, BE, Sharma, P, Mittendorf, EA, Litton, J. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer. Oncotarget 15:238-247, 2024. e-Pub 2024. PMID: 38502947.
33. Zhou, Z, Adrada, BE, Candelaria, RP, Elshafeey, N, Boge, M, Mohamed, RM, Pashapoor, S, Sun, J, Xu, Z, Panthi, B, Son, JB, Guirguis, MS, Patel, MM, Whitman, GJ, Moseley, T, Scoggins, ME, White, JB, Litton, J, Valero, V, Hunt, KK, Tripathy, D, Yang, WT, Wei, P, Yam, C, Pagel, MD, Rauch, GM, Ma, J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 36670144.
34. Xu, Z, Rauch, DE, Mohamed, RM, Pashapoor, S, Zhou, Z, Panthi, B, Son, JB, Hwang, K, Musall, BC, Adrada, BE, Candelaria, RP, Leung, J, Le-Petross, H, Lane, DL, Perez, F, White, JB, Clayborn, A, Reed, BJ, Chen, H, Sun, J, Wei, P, Thompson, A, Korkut, A, Huo, L, Hunt, KK, Litton, J, Valero, V, Tripathy, D, Yang, W, Yam, C, Ma, J. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers 15(19), 2023. e-Pub 2023. PMID: 37835523.
35. Hwang, K, Elshafeey, N, Kotrotsou, A, Chen, H, Son, JB, Boge, M, Mohamed, RM, Abdelhafez, AH, Adrada, BE, Panthi, B, Sun, J, Musall, BC, Zhang, S, Candelaria, RP, White, JB, Ravenberg, EE, Tripathy, D, Yam, C, Litton, J, Huo, L, Thompson, A, Wei, P, Yang, WT, Pagel, MD, Ma, J, Rauch, GM. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiology: Imaging Cancer 5(4), 2023. e-Pub 2023. PMID: 37505106.
36. Zhou, Z, Adrada, BE, Candelaria, RP, Elshafeey, N, Boge, M, Mohamed, RM, Pashapoor, S, Sun, J, Xu, Z, Panthi, B, Son, JB, Guirguis, MS, Patel, MM, Whitman, GJ, Moseley, T, Scoggins, ME, White, JB, Litton, J, Valero, V, Hunt, KK, Tripathy, D, Yang, W, Wei, P, Yam, C, Pagel, MD, Rauch, GM, Ma, J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2023:1-4, 2023. e-Pub 2023. PMID: 38083160.
37. Abuhadra, NK, Sun, R, Yam, C, Rauch, GM, Ding, Q, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Damodaran, S, Virani, K, White, JB, Ravenberg, EE, Sun, J, Choi, J, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Sahin, AA, Valero, V, Symmans, WF, Litton, J, Tripathy, D, Moulder, S, Huo, L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers 15(13), 2023. e-Pub 2023. PMID: 37444385.
38. Yam, C, Mittendorf, EA, Garber, HR, Sun, R, Damodaran, S, Murthy, RK, Ramirez, DL, Karuturi, MS, Layman, RM, Ibrahim, NK, Rauch, GM, Adrada, BE, Candelaria, RP, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Symmans, WF, Prabhakaran, S, Thompson, A, Valero, V, Tripathy, D, Huo, L, Moulder, S, Litton, J. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Research and Treatment 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
39. Abuhadra, NK, Sun, R, Bassett Jr, R, Huo, L, Chang, JT, Teshome, M, Clayborn, A, White, JB, Ravenberg, EE, Adrada, BE, Candelaria, RP, Yang, WT, Ding, Q, Symmans, WF, Arun, BK, Damodaran, S, Koenig, KB, Layman, RM, Lim, B, Litton, J, Thompson, A, Ueno, NT, Piwnica-Worms, H, Hortobagyi, GN, Valero, V, Tripathy, D, Rauch, GM, Moulder, S, Yam, C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: A phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Investigational New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
40. Panthi, B, Adrada, BE, Candelaria, RP, Guirguis, MS, Yam, C, Boge, M, Chen, H, Hunt, KK, Huo, L, Hwang, K, Korkut, A, Lane, DL, Le-Petross, H, Leung, J, Litton, J, Mohamed, RM, Musall, BC, Pashapoor, S, Patel, MM, Perez, F, Son, JB, Thompson, A, Valero, V, Wei, P, White, JB, Xu, Z, Pinsky, L, Tripathy, D, Yang, WT, Ma, J, Rauch, GM. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers 15(4), 2023. e-Pub 2023. PMID: 36831368.
41. Panthi, B, Mohamed, RM, Adrada, BE, Boge, M, Candelaria, RP, Chen, H, Hunt, KK, Huo, L, Hwang, K, Korkut, A, Lane, DL, Le-Petross, H, Leung, J, Litton, J, Pashapoor, S, Perez, F, Son, JB, Sun, J, Thompson, A, Tripathy, D, Valero, V, Wei, P, White, JB, Xu, Z, Yang, W, Zhou, Z, Yam, C, Rauch, GM, Ma, J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Frontiers in Oncology 13, 2023. e-Pub 2023. PMID: 37941561.
42. Chen, H, Ding, Q, Khazai, L, Zhao, L, Damodaran, S, Litton, J, Rauch, GM, Yam, C, Chang, JT, Seth, S, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Virani, K, White, JB, Ravenberg, EE, Song, X, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Routbort, MJ, Sahin, AA, Valero, V, Symmans, WF, Tripathy, D, Wang, WL, Moulder, S, Huo, L. PTEN in triple-negative breast carcinoma: Protein expression and genomic alteration in pretreatment and posttreatment specimens. Therapeutic Advances in Medical Oncology 15, 2023. e-Pub 2023. PMID: 37547448.
43. Musall, BC, Adrada, BE, Candelaria, RP, Mohamed, RM, Abdelhafez, AH, Son, JB, Sun, J, Santiago, L, Whitman, GJ, Moseley, T, Scoggins, ME, Mahmoud, H, White, JB, Hwang, K, Elshafeey, N, Boge, M, Zhang, S, Litton, J, Valero, V, Tripathy, D, Thompson, A, Yam, C, Wei, P, Moulder, S, Pagel, MD, Yang, WT, Ma, J, Rauch, GM. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. Journal of Magnetic Resonance Imaging 56(6):1901-1909, 2022. e-Pub 2022. PMID: 35499264.
44. Chu, YY, Chen, MK, Wei, Y, Lee, H, Xia, W, Wang, Y, Yam, C, Hsu, JL, Wang, HL, Chang, W, Yamaguchi, H, Jiang, Z, Liu, C, Li, CF, Nie, L, Chan, LC, Gao, Y, Wang, SC, Liu, J, Westin, SN, Lee, S, Sood, AK, Yang, L, Hortobagyi, GN, Yu, D, Hung, MC. Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nature Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
45. Wu, C, Jarrett, AM, Zhou, Z, Elshafeey, N, Adrada, BE, Candelaria, RP, Mohamed, RM, Boge, M, Huo, L, White, JB, Tripathy, D, Valero, V, Litton, J, Yam, C, Son, JB, Ma, J, Rauch, GM, Yankeelov, TE. MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Research 82(18):3394-3404, 2022. e-Pub 2022. PMID: 35914239.
46. Yam, C, Abuhadra, NK, Sun, R, Adrada, BE, Ding, Q, White, JB, Ravenberg, EE, Clayborn, A, Valero, V, Tripathy, D, Damodaran, S, Arun, BK, Litton, J, Ueno, NT, Murthy, RK, Lim, B, Báez, L, Li, X, Buzdar, AU, Hortobagyi, GN, Thompson, A, Mittendorf, EA, Rauch, GM, Candelaria, RP, Huo, L, Moulder, S, Chang, JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
47. Sun, X, Zhai, J, Sun, B, Parra Cuentas, ER, Jiang, M, Ma, W, Wang, J, Kang, AM, Kannan, KS, Pandurengan, RK, Zhang, S, Solis Soto, LM, Haymaker, CL, Raso, G, Mendoza Perez, J, Sahin, AA, Wistuba, II, Yam, C, Litton, J, Yang, F. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Modern Pathology 35(5):601-608, 2022. e-Pub 2022. PMID: 34839351.
48. Jimenez, JE, Abdelhafez, AH, Mittendorf, EA, Elshafeey, N, Yung, JP, Litton, J, Adrada, BE, Candelaria, RP, White, JB, Thompson, A, Huo, L, Wei, P, Tripathy, D, Valero, V, Yam, C, Hazle, JD, Moulder, S, Yang, WT, Rauch, GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. European Journal of Radiology 149, 2022. e-Pub 2022. PMID: 35193025.
49. Layman, RM, Lin, Y, Gutierrez-Barrera, AM, Karuturi, MS, Yam, C, Arun, BK. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer medicine 11(6):1474-1483, 2022. e-Pub 2022. PMID: 35128817.
50. Abuhadra, NK, Sun, R, Litton, J, Rauch, GM, Yam, C, Chang, JT, Seth, S, Bassett Jr, R, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Damodaran, S, White, JB, Ravenberg, EE, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Sahin, AA, Valero, V, Symmans, WF, Tripathy, D, Moulder, S, Huo, L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers 14(5), 2022. e-Pub 2022. PMID: 35267631.
51. Shah, VV, Duncan, AD, Jiang, S, Stratton, SA, Allton, K, Yam, C, Jain, A, Krause, PM, Lu, Y, Cai, S, Tu, Y, Zhou, X, Zhang, X, Jiang, Y, Carroll, C, Kang, Z, Liu, B, Shen, J, Gagea Iurascu, M, Sebastian, MM, Huo, L, Gilcrease, M, Powell, RT, Guo, L, Stephan, C, Davies, P, Parker-Thornburg, J, Lozano, G, Behringer, RR, Piwnica-Worms, H, Chang, JT, Moulder, S, Barton, M. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34508101.
52. Yam, C, Yen, EY, Chang, JT, Bassett Jr, R, Al-Atrash, G, Garber, HR, Huo, L, Yang, F, Philips, A, Ding, Q, Lim, B, Ueno, NT, Kannan, KS, Sun, X, Sun, B, Parra Cuentas, ER, Symmans, WF, White, JB, Ravenberg, EE, Seth, S, Guerriero, JL, Rauch, GM, Damodaran, S, Litton, J, Wargo, J, Hortobagyi, GN, Futreal, A, Wistuba, II, Sun, R, Moulder, S, Mittendorf, EA. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clinical Cancer Research 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
53. Yam, C, Rauch, GM, Rahman, T, Karuturi, MS, Ravenberg, EE, White, JB, Clayborn, A, McCarthy, P, Abouharb, S, Lim, B, Litton, J, Ramirez, DL, Saleem, S, Stec, J, Symmans, WF, Huo, L, Damodaran, S, Sun, R, Moulder, S. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
54. Pazina, T, MacFarlane, AW, Bernabei, L, Dulaimi, E, Kotcher, R, Yam, C, Bezman, NA, Robbins, M, Ross, E, Campbell, KS, Cohen, AD. Alterations of NK cell phenotype in the disease course of multiple myeloma. Cancers 13(2):1-22, 2021. e-Pub 2021. PMID: 33435153.
55. Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res 10(2):648-661, 2020. e-Pub 2020. PMID: 32195033.
56. Sun X, Li CW, Wang WJ, Chen MK, Li H, Lai YJ, Hsu JL, Koller PB, Chan LC, Lee PC, Cheng FJ, Yam C, Chen GY, Hung MC. Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. Am J Cancer Res 10(2):564-571, 2020. e-Pub 2020. PMID: 32195027.
57. Yam, C, Esteva, FJ, Patel, MM, Singareeka Raghavendra, A, Ueno, NT, Moulder, S, Hess, KR, Shroff, G, Hodge, S, Koenig, KB, Chavez Mac Gregor, M, Griner, RL, Yeung, SJ, Hortobagyi, GN, Valero, V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: A phase II study. Investigational New Drugs 37(2):345-351, 2019. e-Pub 2019. PMID: 30610588.
58. Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res 9(3):608-618, 2019. e-Pub 2019. PMID: 30949414.
59. Yam, C, Murthy, RK, Rauch, GM, Murray III, JL, Walters, RS, Valero, V, Brewster, A, Bast Jr, RC, Booser, DJ, Giordano, SH, Esteva, FJ, Yang, WT, Hortobagyi, GN, Moulder, S, Arun, BK. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Investigational New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
60. Basho, RK, Yam, C, Gilcrease, M, Murthy, RK, Helgason, T, Karp, DD, Meric-Bernstam, F, Hess, KR, Valero, V, Albarracin, C, Litton, J, Chavez Mac Gregor, M, Hong, DS, Kurzrock, R, Hortobagyi, GN, Janku, F, Moulder, S. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
61. Yam, C, Seth, S, Hess, KR, Mittendorf, EA, Murthy, RK, Damodaran, S, Helgason, T, Huo, L, Thompson, A, Barton, M, Huang, ML, Arribas, E, Lane, DL, Rauch, GM, Adrada, BE, Gilcrease, M, Chang, JT, Moulder, S. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC). Annals of oncology : official journal of the European Society for Medical Oncology 29:viii73-viii74, 2018. e-Pub 2018. PMID: 32138010.
62. Yam, C, Murthy, RK, Valero, V, Szklaruk, J, Shroff, G, Stalzer, CJ, Buzdar, AU, Murray III, JL, Yang, WT, Hortobagyi, GN, Moulder, S, Arun, BK. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Investigational New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
63. Yam, C, Xu, X, Davies, MA, Gimotty, PA, Morrissette, JJ, Tetzlaff, M, Wani, K, Liu, S, Deng, W, Buckley, M, Zhao, J, Amaravadi, RK, Haas, NB, Kudchadkar, RR, Pavlick, AC, Sosman, JA, Tawbi, H, Walker, L, Schuchter, LM, Karakousis, G, Gangadhar, TC. A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600-mutant solid tumors. Clinical Cancer Research 24(1):22-32, 2018. e-Pub 2018. PMID: 29051322.
64. Dai, SC, Goldberg, D, Agarwal, A, Ma, GK, Yam, C, Ahmad, NA, Ginsberg, GG, Jaffe, DL, Kochman, M, Olthoff, KM, Chandrasekhara, V. Endoscopic therapy is effective for recurrent anastomotic biliary strictures after orthotopic liver transplantation. Annals of Hepatology 16(6):924-931, 2017. e-Pub 2017. PMID: 29055929.
65. Yam, C, Mani, S, Moulder, S. Targeting the molecular subtypes of triple negative breast cancer: Understanding the diversity to progress the field. Oncologist 22(9):1086-1093, 2017. e-Pub 2017. PMID: 28559413.
66. Yam, C, Crisalli, L, Luger, SM, Loren, A, Hexner, E, Frey, NV, Mangan, JK, Gao, A, Stadtmauer, EA, Porter, DL, Reshef, R. Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. American journal of hematology 91(9):883-887, 2016. e-Pub 2016. PMID: 27197602.
67. Yam, C, Landsburg, DJ, Nead, KT, Lin, X, Mato, A, Svoboda, J, Loren, A, Frey, NV, Stadtmauer, EA, Porter, DL, Schuster, SJ, Nasta, S. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. American journal of hematology 91(7):672-676, 2016. e-Pub 2016. PMID: 27012928.
68. Yam, C, Zhao, M, Hayashi, K, Ma, H, Kishimoto, H, McElroy, M, Bouvet, M, Hoffman, R. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. Journal of Surgical Research 164(2):248-255, 2010. e-Pub 2010. PMID: 19766244.

Review Articles

1. Chu, YY, Yam, C, Yamaguchi, H, Hung, MC. Biomarkers beyond BRCA: Promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. Journal of biomedical science 29(1), 2022. e-Pub 2022. PMID: 36284291.
2. Yam, C, Ma, BB, Yap, TA. Global implementation of precision oncology. JCO Precision Oncology 5:854-858, 2021. e-Pub 2021. PMID: 34250385.
3. Pegram, M, Zong, Y, Yam, C, Goetz, MP, Moulder, S. Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting(38):65-77, 2018. e-Pub 2018. PMID: 30231328.

Other Articles

1. Adrada, BE, Guirguis, MS, Huo, L, Yam, C, Tripathy, D, Candelaria, RP, Yang, W, Patel, MM, Moseley, T, Whitman, GJ, Leung, J, Le-Petross, H, Lane, DL, Abuhadra, NK, Litton, J, Valero, V, Hunt, KK, Arun, BK, Mohamed, R, Sun, J, Korkut, A, Pashapoor, S, White, JB, Thompson, A, Wei, P, Ma, J, Moulder, S, Rauch, GM Erratum. JCO Precision Oncology 10(5), 2026. PMID: 42150150.

Editorials

1. Yam, C, Hung, M, Hortobagyi, GN. CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. Oncotarget 9(76):34193-34195, 2018. PMID: 30344934.

Abstracts

1. Pazina T, MacFarlane A, Mentik-James A, Yam C, Kotcher R, Campbell KS, Cohen AD. The Phenotype of Natural Killer (NK) Cells in Multiple Myeloma (MM) Patients: Impact on Ex Vivo Responsiveness to the Anti-SLAMF7 Antibody, Elotuzumab. American Society of Hematology Annual Meeting, 2015.
2. Ye Q, Chen K, Alexander A, Upadhyay R, Krishnamurthy S, Yam C, The MDACC Inflammatory Breast Cancer Team, Lucci A, Woodward W, Lim B. Mutational burden and clonal expansion in lymph nodes correlate with IBC postoperative relapse. San Antonio Breast Cancer Symposium.
3. Yam C, Stopfer J, Brandt A, Powers J, Long JM, Maxwell KN, Bradbury AR, Nathanson KL, Domchek SM. Impact of prior knowledge of mutation status on tumor stage in BRCA1/2 mutation carriers with newly diagnosed breast cancer. American Society of Clinical Oncology Annual Meeting.
4. Yam C, Crisalli L, Luger S, Loren A, Hexner EO, Frey N, Mangan J, Gao A, Stadtmauer EA, Porter D, Reshef R. Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity conditioned allogeneic stem-cell transplantation. American Society of Hematology Annual Meeting.
5. Pazina T, MacFarlane A, Mentik-James A, Yam C, Kotcher R, Campbell KS, Cohen AD. The phenotype of natural killer (NK) cells in multiple myeloma (MM) patients: impact on ex vivo responsiveness to the Anti-SLAMF7 antibody, elotuzumab. American Society of Hematology Annual Meeting.
6. Yam C, Landsburg DJ, Lin X, Mato A, Svoboda J, Loren A, Frey N, Stadtmauer EA, Porter D, Schuster SJ, Nasta SD. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with ALK-negative peripheral T cell lymphoma. American Society of Hematology Annual Meeting.
7. Yam C, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran SK, Helgason T, Huo L, Thompson AM, Gilcrease M, Santiago L, Candelaria RP, Rauch G, Adrada B, Symmans WF, Moulder SL. A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS). American Society of Clinical Oncology Annual Meeting.
8. Yam C, Huo L, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans W, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. San Antonio Breast Cancer Symposium.
9. Yam C, Gutierrez Barrera AM, Huang D, Lin X, Litton JK, Arun B. Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing. San Antonio Breast Cancer Symposium.
10. Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans W, Moulder SL, Yang WT. Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer. San Antonio Breast Cancer Symposium.
11. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. San Antonio Breast Cancer Symposium.
12. Yam C, Hess KR, Litton JK, Yang WT, Santiago L, Candelaria RP, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. American Society of Clinical Oncology Annual Meeting.
13. Yam C, Duncan A, Chang JT, Gilcrease MZ, Shah VV, Barton M, Moulder SL. A TRIM24-like mutational signature predicts worse relapse-free survival (RFS) and overall survival (OS) in patients (pts) with metaplastic breast cancer (MpBC). American Association for Cancer Research Annual Meeting.
14. Yam C, Seth S, Hess KR, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Chang JT, Moulder SL. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy in metaplastic breast cancer. European Society of Medical Oncology Congress.
15. Basho RK, Yam C, White JB, Zhao L, Huo L, Mittendorf EA, Thompson AM, Litton JK, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Moulder SL, Damodaran S. Incidence of PI3K pathway alterations and response to neoadjuvant therapy in triple-negative breast cancer. American Society of Clinical Oncology Annual Meeting.
16. Yam C, Alatrash G, Yen E, Garber H, Philips AV, Huo L, Yang F, Bassett Jr RL, Sun X, Roger Parra Cuentas E, Symmans W, Seth S, White JB, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Sun R, Moulder SL, Mittendorf E. Immune phenotype and response to neoadjuvant systemic therapy in triple-negative breast cancer. American Society of Clinical Oncology Annual Meeting.
17. Abuhadra N, Chang C, Yam C, Sun R, Huo L, White J, Ravenberg E, Litton J, Lim B, Ueno NT, Arun B, Tripathy D, Damodaran S, Murthy R, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Mittendorf E, Moulder S, Jenq R. Prospective evaluation of the gut microbiome and response to neoadjuvant therapy in early-stage triple-negative breast cancer. San Antonio Breast Cancer Symposium.
18. Abuhadra N, Yam C, Sun R, Huo L, White J, Ravenberg E, Adrada B, Sahin A, Litton J, Lim B, Ueno NT, Arun B, Tripathy D, Damodaran S, Murthy R, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Lucci A, Mittendorf E, Moulder S, Chang J. Prospective evaluation of patients with metaplastic triple-negative breast cancer: Molecular characteristics and outcomes with neoadjuvant therapy. San Antonio Breast Cancer Symposium.
19. Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelaria RP, Adrada BE, Seth S, Symmans WF, Murthy RK, White JB, Ravenberg E, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Tripathy D, Moulder SL, Litton JK. Neoadjuvant atezolizumab and nab-paclitaxel in patients with triple-negative breast cancer with suboptimal clinical response to doxorubicin and cyclophosphamide. American Society of Clinical Oncology Annual Meeting.
20. Abuhadra N, Chang C, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR. The impact of gut microbial composition on response to neoadjuvant chemotherapy in early-stage triple-negative breast cancer. American Society of Clinical Oncology Annual Meeting.
21. Garrido-Castro AC, Keenan TE, Li T, Lange P, Callahan C, Guerriero J, Tayob N, Anderson L, Yam C, Daniel BR, Carey LA, Nanda R, Winer EP, Mittendorf EA, Tolaney SM. Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan +/- pembrolizumab in PD-L1-negative metastatic triple-negative breast cancer. American Society of Clinical Oncology Annual Meeting.
22. Shah VV, Miao S, Yam C, Chang JT, Barton M, Piwnica-Worms H, Moulder S, Lozano G. Role of TRIM24 in metaplastic breast cancer and nomination of potential therapeutic targets. San Antonio Breast Cancer Symposium.
23. Rauch GM, Cadelaria RP, Guirguis MS, Boge M, Mohamed RM, Elshafeey N, Sun J, Whitman GJ, Leung JWT, Le-Petross HC, Santiago L, Lane DL, Scoggins M, Spak DA, Patel MM, Perez F, White JB, Ravenberg EA, Wei P, Tripathy D, Valero V, Litton JK, Huo L, Yam C, Thompson AT, Ma J, Moulder SL, Yang W, Adrada BE. Integrated model for early prediction of neoadjuvant systemic therapy response in triple-negative breast cancer. San Antonio Breast Cancer Symposium.
24. Guirguis MS, Adrada BE, Candelaria RP, Sun J, Whitman GJ, Yang WT, Boge M, Mohamed RM, Elshafeey NA, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Wei P, Tripathy D, White JB, Ravenberg EA, Huo L, Litton JK, Arun BA, Valero V, Thompson AT, Moulder SL, Yam C, Rauch GM. Prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer using baseline tumor MRI characteristics and imaging patterns of response. San Antonio Breast Cancer Symposium.
25. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Forecasting treatment response to neoadjuvant systemic therapy in triple-negative breast cancer via mathematical modeling and quantitative MRI. San Antonio Breast Cancer Symposium.
26. Zhou Z, Elshafeey NA, Rauch DE, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Tripathy D, Valero V, Yam C, Moulder SL, White JB, Son JB, Pagel MD, Rauch GM, Ma J. Deep learning for early prediction of neoadjuvant chemotherapy response in triple-negative breast cancer. San Antonio Breast Cancer Symposium.
27. Zhou Z, Elshafeey NA, Rauch DE, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, White JB, Litton JK, Valero V, Tripathy D, Yam C, Son JB, Pagel MD, Rauch GM, Ma J. Prediction of pathological complete response to neoadjuvant systemic therapy of triple-negative breast cancers via deep learning. Radiological Society of North America Annual Meeting.
28. Rauch GM, Candelaria RP, Guirguis MS, Sun J, Elshafeey NA, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Musall B, White JB, Wei P, Zhou Z, Pagel M, Ma J, Ravenberg EA, Thompson AT, Huo L, Litton JK, Valero V, Tripathy D, Yam C, Moulder SL, Adrada BE. A composite model for pathologic complete response (pCR) prediction in triple-negative breast cancer. Radiological Society of North America Annual Meeting.
29. Rauch GM, Guirguis MS, Candelaria RP, Elshafeey NA, Sun J, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Thompson AT, Litton JK, Valero V, Tripathy D, Yam C, Moulder SL, Adrada BE. Early prediction of chemo-resistance versus excellent response in triple-negative breast cancer patients with DCE-MRI. Radiological Society of North America Annual Meeting.
30. Guirguis MS, Adrada BE, Candelaria RP, Elshafeey NA, Sun J, Yang W, Boge M, Mohamed RM, Le-Petross HC, Whitman GJ, Lane DL, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Wei P, Hash S, Willis B, Ravenberg EA, Thompson AT, Litton JK, Valero V, Tripathy D, Yam C, Moulder SL, Rauch GM. Prediction of pathologic complete response in triple-negative breast cancer using baseline tumor MRI characteristics and patterns of response during neoadjuvant chemotherapy. Radiological Society of North America Annual Meeting.
31. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Image-informed mathematical modeling to predict patient-specific treatment response to neoadjuvant systemic therapy in triple negative breast cancer. Computational Approaches for Cancers Workshop.
32. Elshafeey N, Hwang KP, Adrada BE, Candelaria RP, Boge M, Mahmoud RM, Chen H, Sun J, Yang W, Kotrotsou A, Musall BC, Son JB, Whitman GJ, Leung JWT, Le-Petross HC, Santiago L, Lane DL, Scoggins ME, Spak DA, Guirguis MS, Patel MM, Perez F, Abdelhafez AH, White JB, Huo L, Ravenberg EA, Wei P, Thompson AT, Damodaran S, Tripathy D, Moulder SL, Yam C, Pagel MD, Ma J, Rauch GM. Radiomics model based on magnetic resonance image compilation (MagIC) as early predictor of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer. San Antonio Breast Cancer Symposium.
33. Iwase T, Fujii T, Yam C, Dong W, Shen Y, Tripathy D, Ueno NT. Quantitative estrogen receptor expression affects pathologic complete response to neoadjuvant chemotherapy in patients with early-stage breast cancer with low expression of HER2. San Antonio Breast Cancer Symposium.
34. Iwase T, Alexander A, Chiv V, Kai M, Kida K, Parker C, Marx AN, Cohen E, Gao H, Reuben J, Wang X, Krishnamurthy S, Liu D, Shen Y, Ramirez D, Tripathy D, Booser D, Yam C, Valero V, Lim B, Ueno NT, Willey JS. Phase II study of Pembrolizumab maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy. San Antonio Breast Cancer Symposium.
35. Mohamed RM, Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Patel MM, Elshafeey NA, Pashapoor S, Zhou Z, Son JB, Hwang K, Le-Petross HC, Leung JWT, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Tripathy D, Yam C, Pagel M, Ma J, Rauch GM. Multi-Parametric MRI-Based Radiomics Models for Early Neoadjuvant Systemic Treatment Response Prediction in Triple Negative Breast Cancer (TNBC). Radiological Society of North America Scientific Assembly and Annual Meeting.
36. Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria R, Chen J, Clayborn A, Damodaran S, Ding Q, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams M, Woodward WA, Yajima C, Ueno NT, Chen K, Rauch G, Huo L, Tripathy D. Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer. San Antonio Breast Cancer Symposium.
37. Zhou Z, Adrada BE, Candelaria RP, Mohamed RM, Pashapoor S, Panthi B, Son JB, Xu Z, Hwang K, Guirguis MS, Yang W, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Moseley T, Scoggins ME, Patel MM, Perez F, White J, Litton JK, Valero V, Tripathy D, Yam C, Pagel M, Rauch GM, Ma J. Deep learning using pre-treatment MRIs and clinical information for prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer. Radiological Society of North America Scientific Assembly and Annual Meeting.
38. Guirguis MS, Adrada BE, Patel MM, Perez F, Candelaria RP, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, White J, Zhou Z, Wei P, Son JB, Hwang K, Panthi B, Pagel M, Huo L, Hunt K, Ravenberg E, Thompson A, Litton JK, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Early prediction of chemoresistance versus excellent response in triple negative breast cancer patients (TNBC) with DCE-MRI. Radiological Society of North America Scientific Assembly and Annual Meeting.
39. Adrada BE, Guirguis MS, Patel MM, Perez F, Candelaria RP, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, White J, Zhou Z, Wei P, Son JB, Hwang K, Panthi B, Pagel M, Huo L, Hunt K, Ravenberg E, Thompson A, Litton JK, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Development of a combined model for early prediction of pathologic complete response (pCR) in Triple Negative Breast Cancer (TNBC) undergoing neoadjuvant therapy (NAT). Radiological Society of North America Scientific Assembly and Annual Meeting.
40. Mohamed RM, Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Patel MM, Elshafeey NA, Pashapoor S, Zhou Z, Son JB, Hwang K, Le-Petross HC, Leung JWT, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Tripathy D, Yam C, Pagel M, Ma J, Rauch GM. Multi-parametric MRI-based radiomics models from tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant systemic therapy in triple negative breast cancer patients. San Antonio Breast Cancer Symposium.
41. Guirguis MS, Adrada B, Patel M, Perez F, Candelaria R, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HTC, Leung J, Whitman GJ, Lane DL, Scoggins ME, Moseley T, White J, Wei P, Son JB, Hwang K-P, Panthi B, Pagel M, Hunt KK, Thompson AM, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer. San Antonio Breast Cancer Symposium.
42. Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang K-P, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Yam C, Pagel M, Ma J, Rauch G. A pre-operative dynamic contrast enhanced MRI-based radiomics models as predictors of treatment response after neoadjuvant systemic therapy in triple negative breast cancer patients. San Antonio Breast Cancer Symposium.
43. Panthi B, Mohamed RM, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Rauch G. Longitudinal DCE-MRI radiomic models for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. San Antonio Breast Cancer Symposium.
44. Lucci A, Addanki S, Kalashnikoca E, Renner D, Kuerer H, Meas S, Sarli V, White J, Rauch G, Tripathy D, Arun B, Yam C, Rodriguez A, Liu MC, Moulder S. Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA.
45. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital twins to forecast treatment response in breast cancer patients. NCI CIRP Annual Virtual Meeting.
46. Wu C, Stowers CE, Kumar S, Xu Z, Yam C, Son JB, Ma J, Tamie JI, Rauch GM, Yankeelov TE, EABF L. Patient-specific digital twins to predict TNBC response to NAT via hybrid modeling and data assimilation. Joint Center for Computational Oncology Annual Research Retreat.
47. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Forecasting response to neoadjuvant systemic therapy in triple-negative breast cancer for personalized medicine via mathematical modeling and quantitative MR imaging. Joint Center for Computational Oncology Annual Research Retreat.
48. Kong E, Yam C, Hill HA, Korkut A. Genomic and Transcriptomic Response Markers of Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer. Keck Annual Research Conference.
49. Kalinsky K, Spring L, Yam C, Ntalla I, Stwalley B, Sjekloca N, Lai C, Kaushiva A, Taylor AJ, Nanda R. Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC). European Society of Medical Oncology Congress.
50. Wang X, Zhao L, Semba T, Song X, Knafl M, Krishnamurthy S, Shao S, Coffer LW, Alexander A, Wood Am Bopparaju S, Woodward WA, Chu R, Zhang J, Woodman S, Futreal A, Yam C, Tripathy D, Ueno NT. Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer. American Association for Cancer Research Annual Meeting.
51. Kumar T, Lin Y, Yan Y, Bai S, Li J, Tran T, Hu M, Ravenberg E, Rauch M Clayborn A, Thompson A, Huo L, Moulder S, Yam C, Navin N. Decoding the natural biology of triple-negative breast cancer and response to chemotherapy by single-cell transcriptomics. American Association for Cancer Research Annual Meeting.
52. Akkoc Mustafayev F, Munsell M, Layman R, Yam C, Gutierrez Barrera A, Arun B. Clinical Implications of Body Mass Index (BMI) in BRCA-associated Advanced Breast Cancer Patients Treated With PARP (Poly ADP-Ribose Polymerase) Inhibitors. San Antonio Breast Cancer Symposium.
53. Xu Z, Pashapoor S, Panthi B, Son JB, Hwang KP, Adrada BE, Candelaria RP, Guirguis MS, Patel MM, Le-Petross H, Leung J, Scoggins ME, Whitman G, Mohamed R, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt K, Moulder S, Litton J, Valero V, Tripathy D, Yang W, Yam C, Rauch GM, Ma J. Tumor segmentation with nn-UNet on dynamic contrast enhanced MR images of triple negative breast cancer. ISMRM & ISMRT Annual Meeting.
54. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Zu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathu D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Deep learning models for automatic segmentation of triple negative breast cancer (TNBC). 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
55. Kalinsky K, Spring L, Yam C, Taylor A, Sjekloca N, Kaushiva A, Lai C, Ntalla I, Nanda R. Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+ in the United States (US). American Society of Clinical Oncology Annual Meeting.
56. Stowers CE, Wu C, Kumar S, Xu Z, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Integrating mechanism-based and data-driven modeling to predict the response of triple negative breast cancer to therapy. San Antonio Breast Cancer Symposium.
57. Rauch GM, Guirguis M, Patel M, Candelaria RP, Mohamed R, Moseley T, Le-Petross HT, Leung J, Whitman G, Lane DL, Scoggins M, Perez F, Sun J, Pashapoor S, Xu Z, White J, Wei P, Reed B, Son JB, Hwang KP, Panthi B, Korkut A, Huo L, Hunt KK, Clayborn A, Litton J, Valero V, Tripathy D, Yam C, Yang W, Ma J, Adrada B. Early prediction of response to neoadjuvant immunotherapy in triple negative breast cancer (TNBC) with DCE-MRI. San Antonio Breast Cancer Symposium.
58. Wu C, Stowers CE, Kumar S, Xu Z, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE, EABR L. Developing MRI-based digital-twins via hybrid modeling and data assimilation to predict triple-negative breast cancer response to neoadjuvant chemotherapy. Joint Center for Computational Oncology - 4th Annual Research Retreat.
59. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross H, Leung JWL, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White JB, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Early prediction of response to neoadjuvant systemic therapy of triple negative breast cancer using radiomics on DCE-MRI. ISMRM & ISMRT Annual Meeting.
60. Wu C, Stowers CE, Xu Z, Lima EABF, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Quantification of tumor-associated vasculature as an imaging biomarker for monitoring the response of triple-negative breast cancer to neoadjuvant chemotherapy. American Association for Cancer Research Annual Meeting.
61. Wu C, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE, Lima EABF. Optimization of a longitudinal imaging protocol to monitor the response of breast cancer to neoadjuvant therapy via Bayesian-based data assimilation. Society of Mathematical Biology Annual Meeting.
62. Zhou Z, Adrada BE, Candelaria RP, Eishafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Zu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
63. Stowers CE, Wu C, Kumar S, Lima EABF, Zu X, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Developing MRI-based digital-twins via mathematical modeling and deep learning to predict the response of triple-negative breast cancer to neoadjuvant therapy. American Association for Cancer Research Annual Meeting.
64. Iwase T, Alexander A, Cohen EN, Gao H, Chiv VY, Kai M, Kida K, Krishnamurthy S, Liu D, Shen Y, Ramirez DL, Reuben A, Tripathy D, Booser DJ, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer. American Society of Clinical Oncology Annual Meeting.
65. Kasi PM, Smirnova S, Nikulin V, Brown JH, Almog N, Ogloblina A, Yam C, Peguero JA, Pandya DM, Kerr D, Fowler N. RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types. American Society of Clinical Oncology Annual Meeting.
66. Akkoc Mustafayev FN, Munsell M, Gutierrez-Barrera AM, Yam C, Layman RM, Arun B. Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience. American Society of Clinical Oncology Annual Meeting.
67. Wu C, Lima EABF, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Optimizing therapeutic regimens via digital twins to improve triple negative breast cancer response to neoadjuvant therapy. San Antonio Breast Cancer Symposium.
68. Niravath P, Mai H, Sun K, Yam C, Meric-Bernstam F, Chervo M, Banaglorioso K, Wink D, Conlon K, Lipkowitz S, Mathur S, Chang J. Phase IB/II Trial of Alpelisib with iNOS Inhibitor and Nab-paclitaxel in Patients with HER2 negative Metastatic or Locally Advanced Metaplastic Breast Cancer. San Antonio Breast Cancer Symposium.
69. Stowers CE, Wu C, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Predicting the response of triple-negative breast cancer to neoadjuvant chemotherapy via biology-based modeling and habitat analysis. San Antonio Breast Cancer Symposium.
70. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Retrospective validation of digital twin-based predictions of personalized triple negative breast cancer response to neoadjuvant therapy regimens. San Antonio Breast Cancer Symposium.
71. Rauch GM, Moseley T, Guirguis M, Whitman G, Candelaria R, Leung J, Patel M, Sun J, Le-Petross H, Lane D, Scoggins M, Perez F, Mohamed RM, Xu Z, Pashapoor S, Son JB, Hwang KP, Chen H, Wei P, Tripathy D, Yang W, Yam C, Ma J, Adrada B. DCE-MRI Tumor volumetric changes predict response to neoadjuvant immunochemotherapy in triple negative breast cancer patients. International Society for Magnetic Resonance in Medicine (ISMRM) & ISMRT Annual Meeting & Exhibition.
72. Stowers CE, Wu C, Xu Z, Kumar S, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Using pre-treatment MRI data to drive an integrated mechanism – and data-driven model to predict the response of breast cancer to therapy. SIAM Conference on Imaging Science.
73. Xu Z, Son JB, Mohamed RM, Adrada B, Wei P, Yam C, Rauch GM, Ma J. SegTNBC: A refined segment anything (SAM) model for MR images of triple-negative breast cancer. IEEE EMBS Annual Conference.
74. Nanda R, Yam C, Spring L, Bhave MA, Ntalla I, Valdez T, Stwalley B, Liang C, Sjekloca N, Lai C, Kalinsky K. Management of neutropenia and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States. San Antonio Breast Cancer Symposium.
75. Pan X, Ercan C, Wang Z, Jr RB, Pinao Gonzales KB, Yam C, Huo L, Yuan Y. AI-derived tumor-infiltrating lymphocytes enhance the model with baseline stromal tumor-infiltrating lymphocytes and Ki67 in predicting pathologic complete response in early stage triple-negative breast cancer prospective trial. San Antonio Breast Cancer Symposium.
76. Yan Y, Lin Y, Kumar T, Bai S, Li J, Tran T, Hu M, Ravenberg E, Rauch M, Clayborn A, Thompson A, Lim B, Huo L, Moulder S, Yam C, Navin N. Decoding the archetypes and eco-hubs of triple-negative breast cancer in responses to chemotherapy. American Association for Cancer Research Annual Meeting.
77. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Patient-specific optimization of therapeutic regimens via digital twins to improve triple negative breast cancer response to neoadjuvant therapy. World Congress on Computational Mechanics and Pan American Congress on Computational Mechanics.
78. Stowers CE, Wu C, Xu Z, Kumar S, Yam C, Bon JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Integrating mechanism-based modeling and MRI data to improve predictions of breast cancer response to chemotherapy. Society of Mathematical Biology Annual Meeting.
79. Mohamed RM, Son JB, Adrada B, Moseley T, Whitman G, Candelaria R, Panthi B, Chen H, Guirguis M, Leung J, Hwang KP, Pashapoor S, Patel M, Scoggins M, Le-Petross H, Lane D, Perez F, Wei P, Xu Z, Tripathy D, Yang W, Yam C, Ma J, Rauch GM. Radiomics and Background Parenchymal Enhancement of Fibroglandular Tissue for Predicting Treatment Response in Triple-Negative Breast Cancer. 2024 ISMRM & ISMRT Annual Meeting & Exhibition.
80. Akkoc Mustafayev FN, Mustafayev NA, Gutierrez AM, Pasyar S, Yam C, Layman RM, Kizub D, Bassett R, Arun B. Clinical outcomes and the 21-gene recurrence score assay in early-stage breast cancer associated with CHEK2, ATM and PALB2 germline pathogenic variants. San Antonio Breast Cancer Symposium.
81. Nandyala M, Wu C, Stowers C, Patel R, Yam C, Ma J, Fuentes D, Rauch GM, Yankeelov TE. Multiphysics and Multiscale Computational Modeling for Predicting Patient-Specific Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer. Moffitt Cancer Center.
82. Stowers CE, Wu C, Lorenzo G, Xu Z, Yam C, Ma J, Rauch GM, Yankeelov TE. Mechanically-coupled, biology-informed modeling for predicting triple-negative breast cancer response to neoadjuvant therapy. World Congress on Computational Mechanics.
83. Hawkins-Westergard D, Dimitrijevic A, Yam C, Layman RM, Ueno NT, Arun B, Lee J. Overcoming Olaparib resistance in BRCA-mutated triple-negative breast cancer: synergistic potential of DNA repair pathway inhibitors. San Antonio Breast Cancer Symposium.
84. Hwang KP, Son JB, Xu Z, Mohamed R, Chen H, Adrada BE, Mosley T, Yam C, Wei P, Yang W, Ma J, Rauch GM. Prediction of Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer Using a 3D Neural Network on Synthetic MR Images. 2024 ISMRM & ISMRT Annual Meeting & Exhibition.
85. Xu Z, Son JB, Adrada BE, Moseley TW, Candelaria RP, Guirguis MS, Patel MM, Whitman GJ, Leung JWT, Le-Petross HTC, Mohamed RM, Pashapoor S, Lane DL, Perez F, Chen H, Sun J, Wei P, Tripathy D, Yang W, Yam C, Rauch GM, Ma J. Deep learning models for predicting responses to neoadjuvant systemic therapy in triple-negative breast cancer using pre-treatment MRI. 2024 ISMRM & ISMRT Annual Meeting & Exhibition.
86. Yam C, Iwase T, Nelson B, Bassett Jr RL, Singareeka A, Whitman G, Karuturi M, Adrada B, Kizub D, Guirguis M, Buzdar A, Moseley T, Nwosu-Iheme A, Kapoor M, Sukumar J, Thomas P, Barcenas C, Ibrahim N, Moscol G, Nasrazadani A, Ramirez D, Wright M, Lee J, Woodward W, Litton J, Hunt K, Giordano S, Tripathy D, Valero V, Huo L, Rauch G, Ueno N. NeoSaci-io: neoadjuvant sacituzumab govitecan (SG) + pembrolizumab (Pb) in patients (pts) with early-stage TNBC experiencing suboptimal response to KEYNOTE-522. San Antonio Breast Cancer Symposium.
87. Leyva-Aranda V, Yam C, Yun C, Ueno N, Lee J, Yun SS, Gallup DF, Yun K. Measuring pembrolizumab response ex-vivo from TNBC patients using the E-slice assay. San Antonio Breast Cancer Symposium.
88. Raghavendra A, Wang Z, Jr R, Damodaran S, Yam C, Valero V, Pohlmann P, Litton J, Meric-Bernstam F, Tripathy D, Adesoye T. Real world outcomes of sacituzumab govitecan in hormone receptor-positive and triple-negative breast cancer: Impact of prior therapy. San Antonio Breast Cancer Symposium.
89. Ranjbar S, Lucas A, Chen P, Shah K, Suchko M, Guerrouahen B, Ercan C, Toro E, Sweeney K, Pan X, Cruz J, Rodriguez B, Reddy N, Yam C, Mantha G, Riben M, Huo L, Yuan Y. Reproducibility and robustness of an AI-based stromal tumor-infiltrating lymphocyte pipeline in triple-negative breast cancer. San Antonio Breast Cancer Symposium.
90. Kalinsky K, Schmid P, Azambuja E, Loi S, Kim S, Yam C, Rapoport B, Im S, Pistilli B, Mchayleh W, Cescon D, Watanabe J, Bañuelas M, Freitas-Junior R, Lortholary A, Gary D, Caldwell K, Harting E, Tolaney S. Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro for previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC). San Antonio Breast Cancer Symposium.
91. Murray S, Nasrazadani A, Yam C, Alexander A, Baranov O, Goncharova D, Paradiso F, Hensley M, The MDACC Inflammatory Breast Cancer Team, Woodward W, Layman R, Saleem S, Valero V, Stauder M, Lucci A, Sun S, Whitman G, Patel M, Le-Petross H, Lu Y, Marx A, Yajima C, Kai M, Villarreal L, Lopez H, Lim B. Trop2 expression and therapeutic opportunities in inflammatory breast cancer. San Antonio Breast Cancer Symposium.
92. Upadhyay R, Alexander A, Ye Q, Chen K, Yam C, Hogan G, Zhang S, LaBella M, Ratzel S, The MDACC Inflammatory Breast Cancer Team, Lucci A, Woodward W, Lim B. Ultrasensitive ctDNA-based MRD monitoring predicts relapse in postoperative HR+ inflammatory breast cancer. San Antonio Breast Cancer Symposium.
93. Lopez E, Nasrazadani A, Baranov O, Smirnov V, Love A, Paradiso F, Hensley M, Layman R, Mouabbi J, Yam C, Nelson B, Sadia S, Valero V, Stauder M, Woodward W, Lucci A, Sun S, Whitman G, Patel M, Le-Petross H, Lu Y, Marx A, Alexander A, Yajima C, Kai M, Villarreal L, Lopez H, Giordano S, Litton J, Bora L. Distinct Immune Landscapes in Inflammatory and Metaplastic Breast Cancer: Insights from Transcriptomic Profiling. San Antonio Breast Cancer Symposium.
94. Rauch GM, Yam C, Moseley TW, Guirguis MS, Patel MM, Leung JWT, Huo X, Whitman GJ, Le-Petross HC, Candelaria RP, Lane DL, Yang WT, Sun J, Huo L, Tripathy D, Litton J, Valero V, Arun B, Hwang KP, Wei P, Ma J, Adrada BE. On-treatment DCE-MRI tumor volume reduction (TBR) predicts response to neoadjuvant immunochemotherapy (NCIT) in patients with triple negative breast cancer (TNBC). Radiological Society of North America Scientific Assembly and Annual Meeting.
95. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-informed mathematical model to practically guide patient-specific optimization of triple-negative breast cancer response to neoadjuvant chemotherapy. 18th U.S. National Congress on Computational Mechanics.
96. Ziyu F, Yuexin L, Xu Z, Son JB, Huo X, Moseley T, Adrada BE, Yam C, Ma J, Rauch GM. Deep learning-based prediction of response to neoadjuvant immunochemotherapy in triple-negative breast cancer based on pretreatment DCE-MRI. International Society for Magnetic Resonance in Medicine.
97. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-informed mathematical model to practically guide patient-specific optimization of triple-negative breast cancer response to neoadjuvant chemotherapy. Joint Mathematics Meetings.
98. Azambuja ED, Schmid P, Kalinsky K, Loi S, Kim S, Yam C, Rapoport B, Im S, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Lara Bañuelas MA, Freitas-Junior R, Bofill JS, Wang X, Zhang Y, Shi L, Chen A, Tolaney SM. Patient-Reported Outcomes With Sacituzumab Govitecan Plus Pembrolizumab vs Chemotherapy Plus Pembrolizumab in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer in the Phase 3 ASCENT-04/KEYNOTE-D19 Study. European Society of Medical Oncology Annual Congress.
99. Leyva-Aranda V, Yam C, Yun C, Ueno N, Lee J, Yun SS, Gallup DF, Yun K. Measuring pembrolizumab response ex-vivo from TNBC patients using the E-slice assay. Nature conferences - the tumor ecosystem.
100. Leyva-Aranda V, Maldonado J, Gallup TD, Kim M, Ueno N, Yam C, Yun SS, Gallup DF, Yun K. E-Slices With Intact TME For Empirical Response Measurements For Immunotherapies And Other Drugs From Human Tumors. Precision Oncology & Diagnostics.
101. Yan Y, Lin Y, Kumar T, Bai S, Thennavan A, Li J, Tran T, Hu M, Rao M, Casasent A, Ravenberg E, Rauch GM, Clayborn A, Tripathy D, Thompson A, Lim B, Huo L, Moulder S, Yam C, Navin N. Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy. San Antonio Breast Cancer Symposium.
102. Lopez E, Smirnov V, Baranov O, Love A, Paradiso F, Hensley M, Nelson B, Yam C, Cancer Team TMIB, Giordano SH, Litton JK, Lim B. Distinct immune landscapes in inflammatory and metaplastic breast cancer: insights from transcriptomic profiling. San Antonio Breast Cancer Symposium.
103. Yam C, Patel M, Sun J, Adrada BE, Raghavendra AS, Litton JK, Mouabbi JA, Iheme AN, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, Rauch GM. Early on-treatment tumor volume reduction predicts response to neoadjuvant chemoimmunotherapy in high risk, early-stage triple negative breast cancer (TNBC). International Neoadjuvant Immunotherapy Across Cancers.
104. Yam C, Radko A, Huo L, Akshara S, Ohanjanyan E, Yudina A, Kushnarev V, Hill H, Abouharb S, Adrada B, Arun B, Barcenas C, Bisen A, Brewster A, Buzdar A, Gregor M, Damodaran S, Garber H, Guirguis M, Hassan A, Ibrahim N, Karuturi M, Kong E, Layman R, Moscol G, Mouabbi J, Murthy R, Nasrazadani A, Nelson B, Iheme A, Oke O, Patel M, Pohlmann P, Ramirez D, Saleem S, Sukumar J, Sun J, Thomas P, Walters R, Wei P, Williams M, Wright M, Woodward W, Hunt K, Litton J, Valero V, Tripathy D, Rauch G, Goldberg M, Korkut A. Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer. San Antonio Breast Cancer Symposium.
105. Tolaney SM, Azambuja ED, Kalinsky K, Loi S, Kim S, Yam C, Rapoport BL, Im S, Pistilli B, McHayleh W, Cescon DW, Watanabe J, Lara A, Freitas-Junior R, Bofill JS, Afshari M, Gary D, Wang L, Lai C, Schmid P. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. American Society of Clinical Oncology Annual Meeting.
106. Nandyala M, Wu C, Stowers CE, Patel R, Yam C, Ma J, Fuentes D, Rauch GM, Yankeelov TE. Predicting and optimizing the response of breast cancer patients to neoadjuvant therapy using a multiscale computational model. American Association for Cancer Research Annual Meeting.
107. Yan Y, Lin Y, Kumar T, Bai S, Thennavan A, Li J, Tran T, Hu M, Rao M, Casasent A, Ravenberg E, Rauch GM, Clayborn A, Tripathy D, Thompson A, Lim B, Huo L, Moulder S, Yam C, Navin N. Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy. American Association for Cancer Research Annual Meeting.
108. Yam C, Patel M, Sun J, Adrada BE, Raghavendra AS, Litton JK, Mouabbi JA, Iheme AN, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, Rauch GM. Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC). American Society of Clinical Oncology Annual Meeting.
109. Leyva-Aranda V, Yam C, Yun C, Ueno N, Lee J, Yun SS, Gallup DF, Yun K. Measuring pembrolizumab response ex-vivo from TNBC patients using the E-slice assay. Society for Immunotherapy of Cancer Annual Meeting.
110. Zhao M, Yoram B, Ma H, Yam C, Li S, Matin A, Hoffman RM. Efficacy of chemotherapy enhanced by targeted bacterial delivery of a prodrug-converting enzyme to a human colon tumor in nude mice. American Association for Cancer Research Annual Meeting.
111. Zhao M, Yam C, Hayashi K, Kaushal S, McElroy M, Bouvet M, Hoffman RM. Human patient colon cancer growth is inhibited by a genetically modified S. typhimurium in nude mice. American Association for Cancer Research Annual Meeting.
112. Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, Bouvet M, Hoffman RM. Targeting a modified Salmonella typhimurium strain to pancreatic-cancer liver metastasis. American Association for Cancer Research Annual Meeting.
113. Dai S, Yam C, Agarwal A, Goldberg DS, Jaffe DL, Kochman ML, Chandrasekhara V. Recurrence of liver transplant-related biliary anastomotic strictures after successful endoscopic therapy. Digestive Disease Week.

Book Chapters

1. Yam C, Roesch E. Oncology Overview (Adjuvant and Neoadjuvant). In: Diagnostic Imaging - Breast.

Letters to the Editor

1. Boddu, P, Oviedo, SP, Rausch, CR, Yam, C, Daver, N, Kantarjian, HM, Kadia, TM. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leukemia and Lymphoma 59: 1486-1489, 2018.
2. Yam, C, Hristov, AC, Schulick, RD. Solitary fibrous tumour of the rectosigmoid wall: Report of a case and review of the literature. Annals of the Academy of Medicine Singapore 40: 192-194, 2011.